Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis
This study is ongoing, but not recruiting participants.
Abbott Biotherapeutics Corp.
Information provided by:
First received: January 15, 2010
Last updated: September 12, 2013
Last verified: August 2012
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||September 2015|
|Estimated Primary Completion Date:||May 2015 (Final data collection date for primary outcome measure)|